Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

被引：12

作者：

Russano, Marco ^{[1
]}

La Cava, Giulia ^{[1
]}

Cortellini, Alessio ^{[1
]}

Citarella, Fabrizio ^{[1
]}

Galletti, Alessandro ^{[2
]}

Di Fazio, Giuseppina Rita ^{[1
]}

Santo, Valentina ^{[1
]}

Brunetti, Leonardo ^{[1
]}

Vendittelli, Alessia ^{[1
]}

Fioroni, Iacopo ^{[1
]}

Pantano, Francesco ^{[1
]}

Tonini, Giuseppe ^{[1
]}

Vincenzi, Bruno ^{[1
]}

机构：

[1] Campus Biomed Univ Rome, Dept Med Oncol, Via Alvaro Portillo 21, I-00128 Rome, Italy

[2] San Camillo Forlanini Hosp, Div Med Oncol, I-00152 Rome, Italy

来源：

CURRENT ONCOLOGY | 2023年 / 30卷 / 02期

关键词：

immunotherapy; non-small cell lung cancer; immune checkpoint inhibitors; PD-1; PD-L1; antibodies; combination strategies; biomarkers; tissue biomarkers; liquid biopsy; IMMUNE CHECKPOINT INHIBITORS; PD-L1; EXPRESSION; NSCLC PATIENTS; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; ADVERSE EVENTS; CHECKMATE; 9LA; PATIENTS PTS; PHASE-III;

D O I：

10.3390/curroncol30020181

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.

引用

页码：2366 / 2387

页数：22

共 50 条

[1] Biomarkers of immunotherapy for non-small cell lung cancer
Shirasawa, Masayuki
Yoshida, Tatsuya
Ohe, Yuichiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (01) : 13 - 22
[2] Biomarkers of immunotherapy in non-small cell lung cancer
Wang, Lingling
Hu, Yue
Wang, Shengchao
Shen, Jiali
Wang, Xiaochen
ONCOLOGY LETTERS, 2020, 20 (05)
[3] Advances in Immunotherapy for Non-Small Cell Lung Cancer
Reckamp, Karen L.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (12) : 847 - 853
[4] Immunotherapy of metastatic non-small cell lung cancer
Sackmann, Sandra
Ogundele, Samuel
Ukena, Dieter
PNEUMOLOGE, 2019, 16 (06): : 353 - 365
[5] Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review
Khwaja, Raida M.
Chu, Quincy S. -C.
CURRENT ONCOLOGY, 2022, 29 (02) : 479 - 489
[6] Therapeutic advances in non-small cell lung cancer
Vallieres, Eric
Peters, Solange
Van Houtte, Paul
Dalal, Paras
Lim, Eric
THORAX, 2012, 67 (12) : 1097 - 1101
[7] Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, Catriona
John, Tom
Wong, Annie
FRONTIERS IN ONCOLOGY, 2024, 14
[8] New advances in immunotherapy for non-small cell lung cancer
Qin, Haifeng
Wang, Fang
Liu, Hui
Zeng, Zhen
Wang, Shasha
Pan, Xin
Gao, Hongjun
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (08): : 2234 - 2245
[9] Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy
Patel, Shetal A.
Weiss, Jared
CLINICS IN CHEST MEDICINE, 2020, 41 (02) : 237 - +
[10] Radiomic biomarkers for the prediction of immunotherapy outcome in patients with metastatic non-small cell lung cancer.
Trebeschi, Stefano
Kurilova, Ieva
Calin, Adriana M.
Lambregts, Doenja M. J.
Smit, Egbert F.
Aerts, Hugo
Beets-Tan, Regina G. H.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →